; and (VII) the average net price of such prescription drug for each year since first being sold in the United States. (xi) Any Federal benefits and amounts and periods of impact for each such benefit received by the manufacturer with respect to the prescription drug, including tax credits, Federal grants, patent applications that benefitted from such grants, patent extensions, exclusivity periods, and waivers of fees. (xii) The percentage of research and development expenditures described in this section that were derived from Federal funds. (xiii) Executive compensation for the chief executive officer, chief financial officer, and the three other most highly compensated executive officers, including bonuses, paid by such manufacturer, and stock options affiliated with the manufacturer that were offered to or accrued by such officers. (xiv) Other information as the Director may require. (B) Bureau review priorities In reviewing submissions under subparagraph (A), the Bureau shall prioritize prescription drugs that meet any of the following criteria: (i) In the top 50th percentile of net spending on prescription drugs under any Federal program, including the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq.) or the Medicaid program under title XIX of such Act ( 42 U.S.C. 1396 et seq.). (ii) In the top 50th percentile of utilization under any Federal program, including such Medicare program or such Medicaid program. (iii) Experienced an increase in the wholesale acquisition cost of 25 percent or more over the preceding 3 years. (iv) Other qualifications, as determined by the Director. (3) Information on prescription drugs approved after enactment With respect to any prescription drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) after the date of enactment of this Act, each manufacturer, not later than 45 days prior to introducing such prescription drug into interstate